title: Proliferation of leukemic B cells in response to SAC and anti-mu. Evidence for different modes of action and comparison to proliferation and differentiation induced by conditioned medium.
abstract: We investigated the proliferative responses and immunoglobulin production of highly purified E-rosette negative largely leukemic B cells from patients with CLL to Staphylococcus aureus Cowan I (SAC) or to SAC in combination with anti-mu or conditioned medium (CM). The latter was derived by stimulating human peripheral blood mononuclear leukocytes with PHA. We observed: (1) that purified E-rosette negative largely leukemic B cells from 25% (five out of 20) of the patients exhibited proliferative responses to SAC; (2) inhibition of SAC-induced proliferation by anti-mu in certain patients, whereas synergism between SAC and anti-mu in inducing proliferative responses in others; (3) the lack of synergism between SAC and CM in inducing proliferative responses, which is in contrast to the strong synergism that was observed between anti-mu and CM in inducing proliferation; and (4) induction or enhancement by SAC alone of Ig production by largely leukemic B-cell populations from few patients with CLL and purified tonsillar B lymphocytes, but not peripheral blood B cells from normal donors. These results suggest that SAC and anti-mu induce proliferation of B cells by different mechanisms and that B-cell proliferation and differentiation is dependent not only on the mitogen but also on the activation state of the cells.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York.
authors.forename: J
authors.initials: J
authors.lastname: Steinberg
authors.forename: C
authors.initials: C
authors.lastname: Bona
authors.forename: A
authors.initials: A
authors.lastname: Polyzos
authors.forename: M A
authors.initials: MA
authors.lastname: Moore
authors.forename: C D
authors.initials: CD
authors.lastname: Platsoucas
mesh_terms: D000276:Adjuvants, Immunologic / Q000276:immunology / Q000494:pharmacology; D000888:Antibodies, Anti-Idiotypic; D001402:B-Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D002454:Cell Differentiation / Q000187:drug effects; D003470:Culture Media / Q000494:pharmacology; D004357:Drug Synergism; D006131:Growth Inhibitors / Q000276:immunology / Q000494:pharmacology; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology*; D007136:Immunoglobulins / Q000096:biosynthesis; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects; D012397:Rosette Formation; D013211:Staphylococcus aureus / Q000276:immunology*; D014407:Tumor Cells, Cultured / Q000276:immunology / Q000473:pathology
chemical_list: D000276:Adjuvants, Immunologic; D000888:Antibodies, Anti-Idiotypic; D003470:Culture Media; D006131:Growth Inhibitors; D007075:Immunoglobulin M; D007136:Immunoglobulins; C044203:anti-IgM